WilmerHale Counsels Constellation Pharmaceuticals in $60M IPO

WilmerHale Counsels Constellation Pharmaceuticals in $60M IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced on July 18, 2018, the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $60 million.

The WilmerHale team representing Constellation is led by Lia Der Marderosian and includes Steven Singer, Craig Hilts, Caroline Dotolo, Hilary Baker-Jennings, Kimberly Wethly and Meghan Walsh.

Read Constellation’s press release about the IPO.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel